--- title: Documenting a complex outpatient psychiatric medication management visit | Nextvisit description: "How to chart a polypharmacy, partial-response med-management visit: interval history, regimen list, assessment reasoning, and plan." url: "http://localhost:3000/guides/complex-psych-medication-management-visit" type: static generatedAt: "2026-09-04T06:57:01.694Z" --- Guide # Documenting a complex outpatient psychiatric medication management visit How to chart a polypharmacy, partial-response med-management visit: interval history, regimen list, assessment reasoning, and plan. Guide / For Psychiatrists, NPs and PAs / 4 min / Published March 10, 2026 / Updated May 3, 2026 The visit is familiar: multi-year history, three or four active diagnoses, four to seven medications, partial response, a new stressor, and a decision to escalate, augment, switch, or hold. The note is harder. Standard SOAP does not hold the chain of reasoning, so the assessment shrinks to two sentences and the HPI becomes six paragraphs of medication history that belongs somewhere else. ## What the visit actually is A complex med-management follow-up has six questions: 1. How is the patient doing now, in their words and on mental status? 1. What has changed since last visit: symptoms, function, life context, adherence? 1. What is the current regimen: doses, durations, tolerability? 1. What is the response and tolerability picture across the regimen? 1. What is the clinical decision today, and why? 1. What is the plan and the reassessment timeline? The note should make all six visible. A tight assessment that ties the answers together is the part the chart hinges on. ## Section by section ### Chief complaint One sentence, close to the patient’s language. “Follow-up on bipolar II, depressive episode, with concern about a flat plateau in mood since the last visit” is a chief complaint. “Follow-up” is not. ### Interval history (not HPI in the classic sense) This is where most complex med-management visits dump too much content. What belongs: - Symptom trajectory since last visit, with patient-reported severity and any objective markers (PHQ-9, GAD-7, MDQ, sleep tracking, side-effect logs). - Medication adherence, with corroboration where relevant (refill history, blood levels for lithium or valproate, UDS for controlled substances). - Functional status: work, school, relationships, sleep, appetite, exercise, substance use. - New stressors or context changes. - Side effects, in the patient’s terms. - Acute events: ED visits, hospitalizations, incidents. What does not belong: - Full medication history. Put it in the medication list if it is not already in the longitudinal chart. - Past psychiatric diagnoses. Those belong in past psychiatric history. - Detailed family history, except where it changes today’s decision. - The differential. That belongs in the assessment. A complex interval history should fit in three to five clear paragraphs. If it sprawls, content is in the wrong section. ### Mental status examination The MSE is where the chart shows you were in the room. Make it specific. Identical MSE paragraphs across visits are the highest-yield target in a chart review. What “specific” looks like: - Affect in observed terms with range and reactivity (“constricted, mildly depressed, reactive within a narrow range”) rather than stock adjectives. - Thought process in observed terms (“linear and goal-directed today, in contrast to the loose associations noted at the prior visit”). - Speech, psychomotor activity, and any cognitive observations from the conversation. - Suicide and homicide risk in the form actually assessed, with reference to the C-SSRS or your standard instrument. - Insight and judgment in clinical terms, not boilerplate. If the MSE is word-for-word the prior visit and the rest of the note describes a change, that inconsistency is a vulnerability. Edit the MSE to match the visit. ### Current regimen and tolerability Render the regimen as a structured list, not prose. Each medication: drug name, dose, frequency, duration on current dose, indication, and tolerability. ``` Lamotrigine 200 mg HS, on this dose since 2024-07, indicated for bipolar II maintenance. Tolerated well, no rash, no cognitive complaints. Bupropion XL 300 mg AM, on this dose since 2025-11, indicated for bipolar II depression augmentation. Mild jitteriness initially, resolved. Quetiapine 50 mg HS, on this dose since 2026-01, indicated for sleep and anxiolysis. Mild morning grogginess, manageable. Hydroxyzine 25 mg HS PRN, used 2-3x/week, indicated for anxiety PRN. No issues. ``` Four lines, not four paragraphs. A covering colleague or a reviewer can scan it. ### Response and tolerability across the regimen A short paragraph that ties symptoms to the current regimen. > Patient is in partial remission on the current regimen. Depressive symptoms are improved from a PHQ-9 of 19 in 2025-11 to 12 today, with most of the improvement in the first 8 weeks of bupropion augmentation. Residual symptoms are concentrated in sleep, energy, and motivation. Anxiety is improved from a GAD-7 of 16 to 9, with quetiapine providing the most subjective benefit at the cost of mild morning grogginess. Tolerability is acceptable across the regimen. No metabolic, hepatic, or cognitive concerns on the current monitoring. That paragraph does the work a templated assessment skips. It connects the patient’s experience to the medications. ### Assessment Answer two questions: what is the formulation today, and what is the decision. > Bipolar II disorder, currently in a partial-response depressive episode of approximately 6 months’ duration, with anxiety as a long-standing comorbidity. The current regimen has produced meaningful but incomplete response. The depressive plateau in the past 4 weeks, in the context of stable adherence and adequate trial duration on the current doses, suggests the regimen has reached its asymptote. The clinical decision today is between augmentation with a third agent, rotation of the bupropion to another stimulating antidepressant, or addition of psychotherapy intensification rather than further pharmacologic change. Patient prefers a non-pharmacologic addition first; agreed. Everything before this sets up the reasoning. Everything after it implements the decision. ### Plan Render by domain: - Medications: continue current regimen at current doses for 4 more weeks. No changes today. - Psychotherapy: increase from biweekly to weekly with the current therapist. Discussed coordination of care. - Monitoring: PHQ-9 and GAD-7 at next visit. Repeat lithium level not indicated this cycle. - Safety: C-SSRS administered today, low acute risk, low to moderate chronic. Standard safety plan in effect. Crisis line reviewed. - Follow-up: 4 weeks. Sooner if symptoms worsen. Make the plan specific, time-bound, and tied to the assessment. ## The decision-justification problem Payer audits and peer reviews focus on the decision. Make the reasoning easy to find. If you continue the regimen, say why. “Adequate trial duration on the current dose, partial response, patient preference for non-pharmacologic intensification first” is reasoning. “Continue current treatment plan” is not. If you escalate, connect symptoms, trial duration, and the next step. “Inadequate response after 12 weeks on bupropion 300 mg with full adherence; rotating to vortioxetine 10 mg daily to assess for differential response in the depressive presentation” is reasoning. If you taper or stop a medication, show the rationale and the monitoring plan for the change. Same pattern in all three: connect the data to the decision in prose, in the assessment, not as a bullet list. ## Where Nextvisit fits AriaMD already has the chart, prior notes, medication history, and scale trends, so today’s interval history can show what changed instead of restating the whole history. The medication list pulls from `/patient/[uuid]/medications`. Treatment Pulse and AI Timeline keep prior responses and decisions visible without paging through notes. Put the clinical-reasoning ask in the med-management template; the custom-template guide at `/guides` covers the editor. See it on your workflow ## Twenty minutes, one mock visit. You leave with a note in your template. We run a mock session live, draft the note, and walk through what the downstream claim would look like. No slides. No sales deck. [Book a demo](https://nextvisit.cal.com/ryan/demo) [Talk to sales](mailto:hello@nextvisit.ai) Live in 2 weeks or less BAA signed by default